Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cipla Remains Upbeat On Abraxane As US Generic Competition Looms

Indian Firm Continuing Talks With FDA For Complex ANDA Product

26 Jan 2022

• By Dean Rudge

Sales growth concept — GxAbraxane is one of several assets set to boost Cipla's top line • Source: Alamy

Related Content

Cipla: $500m North American Sales Boost Possible In Five Years

19 Jan 2022

Accord’s UK Lenalidomide Launch Kicks Off A Year Of Revlimid Competition

19 Jan 2022

Cipla Vice Chair Explores Lung Leadership Vision With Biosimilars Opportunities

12 Jan 2022

Cipla Files ANDA For Advair Rival

18 May 2020

Celgene Settlement With Actavis Allows Abraxane Generics In 2022

27 Jan 2018

BMS Projects 2022 Growth Even With $3bn Hit From Revlimid, Abraxane Generics

11 Jan 2022

Related Companies

Cipla Limited

Additional Topics

United States Commercial Generic Drugs Sales & Earnings Strategy FDA BioPharmaceutical

More from Business

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.